Our study has several strengths, including (1) highlighting functional effects of APOL1 risk variants on macrophage phenotype and function relevant to cardiometabolic and kidney disease, (2) studies in both human and mouse model systems, and (3) identifying a novel pathway that attenuates G1 and G2 effects on inflammation and lipid metabolism in macrophages. Here, APOL1 is linked to kidney disorder.